DPX-Survivac receives orphan drug status from EMA

Release Date: 30-Nov-2016

The US Food and Drug Association (FDA) have granted orphan drug designation Immunovaccine’s leading asset, DPX- Survivac for the treatment of patients with ovarian cancer. The EMA grants orphan designation to rare diseases that are defined as life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. With an estimated 30 million people living in the EU this equates to approximately 250,000 people or less for each rare disease.


For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.